Advaxis, Inc.
ADXSD
Other OTC3.85
USD
+0.30
- -
CIK
0001100397
CUSIP
007624406
Return %
Stock
S&P500
1Y
3.22
26.53
3Y
3.22
76.60
5Y
3.22
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9 Deer Park Drive Monmouth Junction NJ United States of America 08852
- CIK
- 0001100397
- Website
- advaxis.com
- Similar Companies
- Business
- Advaxis, Inc. is a clinical-stage biotechnology company specializing in the development and commercialization of cancer immunotherapies. The company focuses on engineered live attenuated Listeria monocytogenes (Lm)-based immunotherapies designed to generate tumor-specific immune responses to treat solid tumors and infectious diseases. Its core products include proprietary immunotherapy candidates such as ADXS-NEO, ADXS-HOT, and ADXS-PSA, which target various cancers through novel mechanisms involving activation of immune cells. Advaxis also provides contract manufacturing and development services for its pipeline and strategic partners. Founded in 2005, Advaxis is headquartered in Princeton, New Jersey, and operates primarily within the United States, with clinical trials and collaborations extending globally. In recent developments over the last 1-2 years, Advaxis has pursued strategic collaborations and expanded its immunotherapy pipeline to include next-generation programs combining its Lm-based platform with checkpoint inhibitors and other immuno-oncology agents. The company has engaged in partnerships aimed at broadening its clinical indications and enhancing product development capabilities. Furthermore, Advaxis continues to focus on advancing its clinical trials and regulatory submissions to accelerate commercialization pathways. There have been no public reports of recent name changes or reorganizations, but the firm remains active in strategic business expansions and research collaborations within the immuno-oncology sector. Advaxis serves the biopharmaceutical and healthcare industries, targeting oncologists, researchers, healthcare providers, and patients in need of novel cancer immunotherapies. Its product development emphasizes immunotherapy innovation, including targeting neoantigens and tumor-associated antigens, to transform cancer treatment paradigms. The company’s operations and clinical research footprint extend beyond the U.S. into collaborative international sites to capture diverse patient populations and regulatory environments. Advaxis, Inc. is a standalone entity publicly traded under the ticker ADXSD, with a focus on delivering next-generation immunotherapies leveraging its proprietary Lm technology platform and advancing cancer treatment through innovative biotech solutions. The company maintains its research headquarters in Princeton, New Jersey, continuing to develop proprietary and partnered products within the immuno-oncology field.